Search by
Poster Number

1, 2, 3, 4,
5, 6, 7, 8,
9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73

Click on the Poster to View the Poster Page

Integrated Interval Analysis of Clinical Trial Data to Evaluate the Long-Term Safety of Risankizumab in Patients With Psoriatic Disease...

Safety and Efficacy of Risankizumab in Genital and Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16 Eingun...

Patient preference over other topicals, perception of cream usability, treatment adherence and satisfaction among patients with...

Impact of calcipotriene and betamethasone dipropionate cream with PAD technology (CAL/BDP PAD cream) on patient symptoms, functioning,...

Impact of calcipotriene and betamethasone dipropionate cream with PAD technology (CAL/BDP PAD cream) on scalp-PGA success, S-mPASI and...

Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body: Improvements in Patient-Reported Outcomes in the ARRECTOR Trial...

Efficacy and Safety of Brodalumab in Patients With Moderate-to-Severe Plaque Psoriasis and Inadequate Response to Prior Biologics Kim...

Brodalumab: Seven-Year US Pharmacovigilance Report Mark Lebwohl, John Koo, April Armstrong, Bruce Strober, Amber Blair, Soo Han Yoon,...

Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With...

Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque...

Zasocitinib (TAK-279), An Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by...

Zasocitinib (TAK-279), aA Oral, Allosteric, Highly Selective TYK2 Inhibitor, Reduced PASI Body Region and Individual Component Scores in...

Real-World Treatment Patterns in Patients with Psoriasis Receiving Tildrakizumab Compared to Ustekinumab George Han, Lynn Huynh, Enrico...